Fulcrum Therapeutics, Inc. (FULC)
NASDAQ
3.68
0.00 (0.00%)
Closed
Oct 23, 2026
Day's Range
3.643.69
52 wk Range
2.8315.74
Financial Statements - FULC - Fulcrum Therapeutics, Inc.
Revenue
0▼ 100.0%
Net Income
-74.88M▼ 670.0%
EBITDA
-83.37M▼ 415.4%
Free Cash Flow
-60.37M▼ 2319.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 80M | 2.80M | 6.34M | 19.16M | 8.82M |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -84.76M | -19.83M | -110.66M | -112.13M | -81.05M | -71.61M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 9.88M | 10.10M | 13.32M | 2.26M | 207K | 792K |
| Pre Tax Income | -74.88M | -9.72M | -97.33M | -109.87M | -80.84M | -70.81M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -74.88M | -9.72M | -97.33M | -109.87M | -80.84M | -70.81M |
| EPS Basic | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| EPS Diluted | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 |
| Basic Shares Outstanding | 63.35M | 61.98M | 61.31M | 44.99M | 35.36M | 25.35M |
| Diluted Shares Outstanding | 63.35M | 61.98M | 61.31M | 44.99M | 35.36M | 25.35M |
| Ebit | -84.76M | -19.83M | -110.66M | -112.13M | -81.05M | -71.61M |
| Ebitda | -83.37M | -16.17M | -108.49M | -109.29M | -78.53M | -69.23M |
| Net Income Continuous Operations | -74.88M | -9.72M | -97.33M | -109.87M | -80.84M | -70.81M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
